Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 10,800 shares, a decline of 6.9% from the October 15th total of 11,600 shares. Based on an average daily trading volume, of 8,500 shares, the short-interest ratio is presently 1.3 days. Approximately 0.1% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Benchmark reissued a “speculative buy” rating and set a $8.00 target price on shares of Anebulo Pharmaceuticals in a research report on Tuesday, October 1st.

Anebulo Pharmaceuticals Price Performance

Anebulo Pharmaceuticals stock opened at $1.59 on Monday. The business has a fifty day moving average price of $1.91 and a 200-day moving average price of $2.12. Anebulo Pharmaceuticals has a 1-year low of $1.46 and a 1-year high of $3.30. The stock has a market capitalization of $41.19 million, a price-to-earnings ratio of -5.29 and a beta of -1.00.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last issued its quarterly earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.08. On average, equities research analysts anticipate that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.